BioNTech’s 82% Response Rate and $17 Billion Cushion Set the Stage for a Pivotal Earnings Week

BioNTech faces a pivotal week as Q1 earnings loom, with investors focused on cash reserves, oncology pipeline progress, and the founders' exit amid falling Covid vaccine revenue.

The German biotech group is entering a defining stretch. After a rocky March that saw its stock plunge on news of a leadership shake-up, BioNTech has clawed back some ground — the shares closed Friday at €88.20, up roughly 14% over the past month. But the real test begins Tuesday, when management unveils first-quarter results for the first time since the founders announced their departure.

Investors are shifting their focus away from top-line growth. Revenue from the Covid-19 vaccine franchise continues to shrink, and the company’s own guidance points to full-year sales of between €2.0 billion and €2.3 billion. Meanwhile, the cost of pivoting to oncology is rising fast: research and development spending is expected to hit as much as €2.5 billion in 2025, up from earlier projections of €2.2 billion. That burn rate makes the balance sheet the star of the show.

BioNTech ended last year with roughly €17 billion in cash and equivalents — a war chest that gives it room to fund multiple late-stage trials without near-term revenue pressure. At the end of 2025, that figure stood at approximately €17.2 billion, according to the latest filings. The key question for analysts on Tuesday will be how quickly that cushion is shrinking.

Pipeline momentum builds

The oncology strategy is gaining traction where it matters most: in the clinic. The experimental bispecific antibody Pumitamig posted an 82% objective response rate in a Phase 2 lung cancer study when combined with chemotherapy, with median overall survival reaching nearly 17 months. That data has put BioNTech ahead of rival Merck in the eyes of some analysts.

H.C. Wainwright’s Robert Burns reiterated his buy rating and $130 price target late last month, arguing the Mainz-based drugmaker’s candidate is clearly outpacing the competition. The broader analyst consensus sits at a similar level, though the range of estimates is unusually wide — the most bullish forecast tops out at $171. With Wall Street reopening after the holiday, the stock is set to start the week near $97.

BioNTech is currently running seven Phase 3 studies for Pumitamig, and management has flagged six more late-stage trials set to begin before year-end. Market watchers expect seven significant data readouts from the pipeline over the course of 2025. Tuesday’s earnings call will provide the first hard update on patient enrollment in those ongoing studies — a catalyst that could move the stock either way.

Board reshuffle and founder exit

The annual general meeting in mid-May adds another layer of complexity. Shareholders will vote on expanding the supervisory board with two new oncology specialists, a move designed to strengthen governance as the company deepens its cancer focus. The agenda also includes a proposal to carry forward the full retained profit and a vote on new authorized capital.

All of this unfolds against the backdrop of a leadership transition. U?ur ?ahin and Özlem Türeci are stepping down from operational roles at the end of 2026 to launch a new mRNA venture. The March announcement sent the stock into a tailspin from which it has only partially recovered. But some analysts see an upside: Leerink Partners argues that a strong new CEO could actually re-rate the shares.

For now, the immediate catalyst is Tuesday’s numbers. With €17 billion in the bank, a pipeline showing real clinical signals, and a board in flux, BioNTech’s transformation is entering its most consequential phase. The earnings report will provide the next concrete data point on whether the company has the financial stamina to see it through.